1194376-46-9

Basic information

• Product Name: 4-bromo-7-fluorobenzofuran
• Synonyms: 4-bromo-7-fluorobenzofuran;4-Bromo-7-fluoro-1-benzofuran
• CAS NO: 1194376-46-9
• Molecular Formula: C8H4BrFO
• Molecular Weight: 215.03
• Mol File: 1194376-46-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 232.6±20.0 °C(Predicted)
• Appearance: /
• Density: 1.696±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 4-bromo-7-fluorobenzofuran(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-7-fluorobenzofuran(1194376-46-9)
• EPA Substance Registry System: 4-bromo-7-fluorobenzofuran(1194376-46-9)

Safety Data

• Hazardous Substances Data: 1194376-46-9(Hazardous Substances Data)

Upstream product

• 112204-58-7 5-Bromo-2-fluorophenol 

Relevant articles and documents

1,3-disubstituted ketene compound and application thereof

The invention relates to a 1,3-disubstituted ketene compound with a structure as shown in a formula (I) and application thereof. The compound mainly activates a PPAR (Peroxisome Proliferators-Activated Receptor) alpha, and also has excitation activity for PPPA delta and PPPA gamma. The 1,3-disubstituted ketene compound can be used for treating various diseases related to the PPAR regulation abnormality, such as NASH (nonalcoholic steatohepatitis), and particularly treating nonalcoholic hepatitis, also has potentials for treating diabetes, obesity, fibrotic diseases, cardiovascular diseases (comprising a heart failure, atherosclerosis and the like), kidney diseases (comprising chronic nephrosis, a kidney failure and the like), brain degenerative diseases (comprising the alzheimer disease and the like) and the like, and has higher application value. The formula is shown in the description.

NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OSTEOPOROSIS

Novel tricyclic compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing osteoporosis and similar conditions. The compounds are effective as calcium sensing receptor antagonists. Pharmaceutical compositions and methods of treatment are also included.